Skip to main content
Matthew Macaluso, DO, Psychiatry, Birmingham, AL

MatthewMacalusoDO

Psychiatry Birmingham, AL

Associate Professor, Psychiatry and Behavioral Sciences, University Kansas School of Medicine

Dr. Macaluso is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Macaluso's full profile

Already have an account?

  • Office

    1717 6th Ave S
    Birmingham, AL 35233
    Phone+1 800-822-8816
    Fax+1 316-293-1863

Education & Training

  • University of Kansas (Wichita)
    University of Kansas (Wichita)Residency, Psychiatry, 2005 - 2009
  • Rowan University School of Osteopathic Medicine
    Rowan University School of Osteopathic MedicineClass of 2005
  • Rutgers University Behavioral Health Care
    Rutgers University Behavioral Health CareBA, Chemistry, Cum Laude, 2001

Certifications & Licensure

  • KS State Medical License
    KS State License 2009 - 2025
  • AL State Medical License
    AL State License 2020 - 2024
  • FL State Medical License
    FL State License 2016 - 2018
  • NJ State Medical License
    NJ State License 2006 - 2010
  • American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

  • Early Career Achievement in Medicine Award University of Kansas Alumni Association, 2015
  • Chair’s Award of Appreciation Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine-Wichita, 2014
  • Fellow American Psychiatric Association, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Par...  
    Preskorn SH, Macaluso M, Journal of Psychiatric Practice, 1/1/2016
  • Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Par...  
    Macaluso M. Flynn A. Preskorn SH, Journal of Psychiatric Practice, 1/1/2016
  • Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Par...  
    Macaluso M, Flynn A, Preskorn SH, Journal of Psychiatric Practice, 1/1/2016
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Transgender health resident education: Assessing short term knowledge and attitude changes
    Houssayni S, Zackula R, Nilsen K, Melhado T, Macaluso M, KUSM-W Research Forum, 1/1/2016
  • Using Standardized Patient Technology as a Tool for Promoting Residents to Indirect Supervision
    Richardson T, Macaluso M, Lochmann D, Parmley M, Kalu W, Lincoln J, KUSM-W Research Forum, 1/1/2016
  • Using Facilitated Discussion, Case Review, and Self Study to Teach Residents Appropriate Boundaries with Medical Students
    Macaluso M, Nevins C, Wehler C, Annual Meeting of the American Association of Directors of Psychiatry Residency Training/KUSM-W Research Forum, Austin, TX, 1/1/2016
  • Join now to see all

Lectures

  • Medical Student Small Group Discussions on Psychopharmacology 
    Kansas University School of Medicine-Wichita - 1/1/2016
  • Generalized Anxiety Disorder 
    Via Christi Saint Francis Campus and Via Christi Saint Joseph Campus, 2013; Wesley Hospital, 2013; V - 1/17/2014
  • Giving Feedback, From Basics to Difficult Cases 
    1/30/2010
  • Join now to see all

Other

Press Mentions

  • Winter Woes: Understanding Seasonal Affective Disorder
    Winter Woes: Understanding Seasonal Affective DisorderNovember 8th, 2024
  • How the COVID-19 Pandemic Changed Society
    How the COVID-19 Pandemic Changed SocietyMarch 14th, 2022
  • PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Amyotrophic Lateral Sclerosis
    PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Amyotrophic Lateral SclerosisAugust 4th, 2021
  • Join now to see all

Professional Memberships